← Back to Search

Virus Therapy

Sendai virus vaccine for Parainfluenza

Phase 1

Waitlist Available

Led By Elisabeth Adderson, MD

Research Sponsored by St. Jude Children's Research Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months after enrollment complete

Awards & highlights

Study Summary

This trial is investigating a new experimental vaccine to prevent croup, which is an illness of young children caused by a virus. The vaccine is given by placing liquid drops in the nose and is made from a virus that is similar to the one that causes croup, but has never been found to cause illness in people.

Eligible Conditions

Parainfluenza
Viral Respiratory Infection

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months after enrollment complete

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months after enrollment complete

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months after enrollment complete for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine if a child's body responds to the presence of the Sendai virus by making proteins in the blood called antibodies that can find and kill the croup virus

To determine if giving live Sendai virus (in the form of a vaccine) to children through their nose is safe (causes no serious illness)

Trial Design

1Treatment groups

Experimental Treatment

Group I: ParticipantsExperimental Treatment1 Intervention

Participants will be studied in three cohorts: Healthy seropositive children 3 years up to 6 years Healthy seropositive toddlers 12 months up to 24 months Healthy seronegative toddlers 12 months up to 24 months. Each cohort will receive Sendai virus vaccine.

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor

428 Previous Clinical Trials

5,306,559 Total Patients Enrolled

Elisabeth Adderson, MDPrincipal InvestigatorSt. Jude Children's Research Hospital

1 Previous Clinical Trials

258 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential adverse effects could arise from administering the Sendai virus vaccine?

"The safety of Sendai virus vaccine is ranked as a 1 due to the limited data available in this Phase 1 trial, which does not provide sufficient evidence for efficacy and safety."

Answered by AI

Does this research grant access to individuals aged sixty and over?

"This clinical trial has set its age range as 12 months to 6 years old."

Answered by AI

Are there still vacancies in this research project that patients can participate in?

"Based on the information from clinicaltrials.gov, this experiment is not presently accepting applicants. It was initially posted back in May 2005 and last updated on June 8th 2022. Although it isn't recruiting currently, there are 123 other trials actively searching for participants."

Answered by AI

Who is the ideal candidate for participation in this clinical experiment?

"For inclusion in the trial, 54 individuals aged one year to six years old must have parainfluenza and be unvaccinated within 30 days of receiving the study vaccine."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

2005. "A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00186927.